Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors
BOSTON , Sept. 04, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by  Ziopharm Oncology , Inc. (Nasdaq:ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued.
View HTML
Toggle Summary Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Company Focused on Responding to FDA for Third-generation Trial NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens in 4Q2018 Controlled IL-12 Monotherapy, Combination Studies Advancing Changes to Board of Directors and New Staff Illustrate Company Growth
View HTML
Toggle Summary Ziopharm Oncology Announces Changes to its Board of Directors
Scott Tarriff , CEO of Eagle Pharmaceuticals , Elected Lead Director Sir Murray Brennan , M.D., former U.S. Sen. Wyche Fowler to Step Down Paratek Pharmaceuticals CFO Doug Pag á n and Scholar Rock COO Elan Ezickson Nominated to Board Directors BOSTON , Aug.
View HTML
Toggle Summary Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8
BOSTON , July 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Wednesday, Aug. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the second quarter
View HTML
Toggle Summary Ziopharm Oncology Board Responds to Recent Stock Price Decline
-  Executing on clinical and business development with plans to add new Board members and expand management team   -  Annual meeting of stockholders is Sept. 18 BOSTON , July 26, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next
View HTML
Toggle Summary Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Phase 1 trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with nivolumab for treatment of recurrent glioblastoma BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing
View HTML
Toggle Summary Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
BOSTON , June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration ( FDA ) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in
View HTML
Toggle Summary Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
- Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers - Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20mg veledimex cohort who received Controlled IL-12 as a single agent - Over expression of immune checkpoint biomarkers demonstrated
View HTML
Toggle Summary Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
-       Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers -       IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma -       Results further support development of
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
-Expanding Controlled IL-12 platform to explore additional tumor types -Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans -ASCO poster to detail IL-12 data in breast cancer, glioblastoma, highlight potential for combination with checkpoint inhibitors
View HTML